Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Osteoporosis 2Musculoskeletal Diseases 2Hyperparathyroidism 2Humoral Hypercalcemia Of Malignancy 2Endocrine System Diseases 2Neoplasms 1Bone Diseases, Endocrine 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × parathyroid hormone-related peptide (1-36) × Clear all
NCT00580788 2016-02-11

One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study

University of Pittsburgh

Phase EARLY_PHASE1 Completed
14 enrolled 16 charts
Head & Neck

Humoral Hypercalcemia Of Malignancy, Endocrine System Diseases, Hyperparathyroidism, Musculoskeletal Diseases, Neoplasms, Osteoporosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡